Treatment of orbital myositis with adalimumab (Humira).

Abstract	Adalimumab is a fully humanized IgG1 monoclonal antibody to tumor necrosis factor-a. We describe 2 patients (17 and 13 years of age) with refractory, steroid-dependent, recurrent nonspecific orbital myositis not controlled with standard immunosuppressive medications. Both improved with adalimumab treatment, allowing reduction in corticosteroid dosage without disease flare.
Authors	Alexa B Adams, Michael Kazim, Thomas J A Lehman
Journal	The Journal of rheumatology (J Rheumatol) Vol. 32 Issue 7 Pg. 1374-5 (Jul 2005) ISSN: 0315-162X [Print] Canada
PMID	15996084 (Publication Type: Case Reports, Journal Article)
Chemical References	Adrenal Cortex Hormones Antibodies, Monoclonal Antibodies, Monoclonal, Humanized Tumor Necrosis Factor-alpha Adalimumab
Topics	Adalimumab Adolescent Adrenal Cortex Hormones (administration & dosage) Antibodies, Monoclonal (administration & dosage) Antibodies, Monoclonal, Humanized Drug Therapy, Combination Female Humans Orbital Pseudotumor (drug therapy) Tumor Necrosis Factor-alpha (antagonists & inhibitors, immunology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!